Detailed price information for Preveceutical Medical Inc (PRVCF) from The Globe and Mail including charting and trades.

The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell immunotherapy. This update removes previous Limitations of Use for patients with ...

It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.

This engagement begins as a defined pilot, with a clear path to expand into a multi-study commercial relationship based on results. For Lunai, this is the kind of near-term work that can translate ...

Nanomedicine, an interdisciplinary field merging the power of nanotechnology with the intricacies of medicine, has revolutionized healthcare on a scale previously unimaginable. By manipulating ...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ...

Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug ...

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

Cycle Group Holdings Limited has completed its acquisition of Applied Therapeutics Inc., a clinical-stage biopharmaceutical company.